These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 35038955

  • 1. MicroRNA-665-3p exacerbates nonalcoholic fatty liver disease in mice.
    Yu Y, Tian T, Tan S, Wu P, Guo Y, Li M, Huang M.
    Bioengineered; 2022 Feb; 13(2):2927-2942. PubMed ID: 35038955
    [Abstract] [Full Text] [Related]

  • 2. MicroRNA-137-3p Improves Nonalcoholic Fatty Liver Disease through Activating AMPKα.
    Yu Y, He C, Tan S, Huang M, Guo Y, Li M, Zhang Q.
    Anal Cell Pathol (Amst); 2021 Feb; 2021():4853355. PubMed ID: 35004133
    [Abstract] [Full Text] [Related]

  • 3. Hepatocyte-derived extracellular vesicles promote endothelial inflammation and atherogenesis via microRNA-1.
    Jiang F, Chen Q, Wang W, Ling Y, Yan Y, Xia P.
    J Hepatol; 2020 Jan; 72(1):156-166. PubMed ID: 31568800
    [Abstract] [Full Text] [Related]

  • 4. MicroRNA-376b-3p ameliorates nonalcoholic fatty liver disease by targeting FGFR1 and regulating lipid oxidation in hepatocytes.
    Wang XY, Lu LJ, Li YM, Xu CF.
    Life Sci; 2022 Nov 01; 308():120925. PubMed ID: 36057399
    [Abstract] [Full Text] [Related]

  • 5. MicroRNA-194 inhibition improves dietary-induced non-alcoholic fatty liver disease in mice through targeting on FXR.
    Nie H, Song C, Wang D, Cui S, Ren T, Cao Z, Liu Q, Chen Z, Chen X, Zhou Y.
    Biochim Biophys Acta Mol Basis Dis; 2017 Dec 01; 1863(12):3087-3094. PubMed ID: 28951211
    [Abstract] [Full Text] [Related]

  • 6. Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease via the Sirt1/AMPK and NF-κB signaling pathways.
    Li CX, Gao JG, Wan XY, Chen Y, Xu CF, Feng ZM, Zeng H, Lin YM, Ma H, Xu P, Yu CH, Li YM.
    World J Gastroenterol; 2019 Sep 14; 25(34):5120-5133. PubMed ID: 31558861
    [Abstract] [Full Text] [Related]

  • 7. Liensinine alleviates high fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD) through suppressing oxidative stress and inflammation via regulating TAK1/AMPK signaling.
    Liang L, Ye S, Jiang R, Zhou X, Zhou J, Meng S.
    Int Immunopharmacol; 2022 Mar 14; 104():108306. PubMed ID: 34999396
    [Abstract] [Full Text] [Related]

  • 8. MicroRNA-223 Ameliorates Nonalcoholic Steatohepatitis and Cancer by Targeting Multiple Inflammatory and Oncogenic Genes in Hepatocytes.
    He Y, Hwang S, Cai Y, Kim SJ, Xu M, Yang D, Guillot A, Feng D, Seo W, Hou X, Gao B.
    Hepatology; 2019 Oct 14; 70(4):1150-1167. PubMed ID: 30964207
    [Abstract] [Full Text] [Related]

  • 9. Liver MicroRNA-291b-3p Promotes Hepatic Lipogenesis through Negative Regulation of Adenosine 5'-Monophosphate (AMP)-activated Protein Kinase α1.
    Meng X, Guo J, Fang W, Dou L, Li M, Huang X, Zhou S, Man Y, Tang W, Yu L, Li J.
    J Biol Chem; 2016 May 13; 291(20):10625-34. PubMed ID: 27013659
    [Abstract] [Full Text] [Related]

  • 10. Repression of MicroRNA-124-3p Alleviates High-Fat Diet-Induced Hepatosteatosis by Targeting Pref-1.
    Wang G, Zou H, Lai C, Huang X, Yao Y, Xiang G.
    Front Endocrinol (Lausanne); 2020 May 13; 11():589994. PubMed ID: 33324345
    [Abstract] [Full Text] [Related]

  • 11. MicroRNA-31-5p Exacerbates Lipopolysaccharide-Induced Acute Lung Injury via Inactivating Cab39/AMPKα Pathway.
    Jiang WL, Zhao KC, Yuan W, Zhou F, Song HY, Liu GL, Huang J, Zou JJ, Zhao B, Xie SP.
    Oxid Med Cell Longev; 2020 May 13; 2020():8822361. PubMed ID: 33101593
    [Abstract] [Full Text] [Related]

  • 12. Hepatocyte miR-34a is a key regulator in the development and progression of non-alcoholic fatty liver disease.
    Xu Y, Zhu Y, Hu S, Pan X, Bawa FC, Wang HH, Wang DQ, Yin L, Zhang Y.
    Mol Metab; 2021 Sep 13; 51():101244. PubMed ID: 33930596
    [Abstract] [Full Text] [Related]

  • 13. Upregulation of miR-181a impairs lipid metabolism by targeting PPARα expression in nonalcoholic fatty liver disease.
    Huang R, Duan X, Liu X, Cao H, Wang Y, Fan J, Wang B.
    Biochem Biophys Res Commun; 2019 Jan 22; 508(4):1252-1258. PubMed ID: 30558790
    [Abstract] [Full Text] [Related]

  • 14. Celastrol ameliorates liver metabolic damage caused by a high-fat diet through Sirt1.
    Zhang Y, Geng C, Liu X, Li M, Gao M, Liu X, Fang F, Chang Y.
    Mol Metab; 2017 Jan 22; 6(1):138-147. PubMed ID: 28123944
    [Abstract] [Full Text] [Related]

  • 15. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease.
    Long JK, Dai W, Zheng YW, Zhao SP.
    Mol Med; 2019 Jun 13; 25(1):26. PubMed ID: 31195981
    [Abstract] [Full Text] [Related]

  • 16. LncRNA NEAT1-MicroRNA-140 axis exacerbates nonalcoholic fatty liver through interrupting AMPK/SREBP-1 signaling.
    Sun Y, Song Y, Liu C, Geng J.
    Biochem Biophys Res Commun; 2019 Aug 20; 516(2):584-590. PubMed ID: 31239155
    [Abstract] [Full Text] [Related]

  • 17. NAD+-boosting therapy alleviates nonalcoholic fatty liver disease via stimulating a novel exerkine Fndc5/irisin.
    Li DJ, Sun SJ, Fu JT, Ouyang SX, Zhao QJ, Su L, Ji QX, Sun DY, Zhu JH, Zhang GY, Ma JW, Lan XT, Zhao Y, Tong J, Li GQ, Shen FM, Wang P.
    Theranostics; 2021 Aug 20; 11(9):4381-4402. PubMed ID: 33754067
    [Abstract] [Full Text] [Related]

  • 18. Hepatic FNDC5 is a potential local protective factor against Non-Alcoholic Fatty Liver.
    Canivet CM, Bonnafous S, Rousseau D, Leclere PS, Lacas-Gervais S, Patouraux S, Sans A, Luci C, Bailly-Maitre B, Iannelli A, Tran A, Anty R, Gual P.
    Biochim Biophys Acta Mol Basis Dis; 2020 May 01; 1866(5):165705. PubMed ID: 32001301
    [Abstract] [Full Text] [Related]

  • 19. An Endoplasmic Reticulum Stress-MicroRNA-26a Feedback Circuit in NAFLD.
    Xu H, Tian Y, Tang D, Zou S, Liu G, Song J, Zhang G, Du X, Huang W, He B, Lin W, Jin L, Huang W, Yang J, Fu X.
    Hepatology; 2021 Apr 01; 73(4):1327-1345. PubMed ID: 32567701
    [Abstract] [Full Text] [Related]

  • 20. A novel role of CRTC2 in promoting nonalcoholic fatty liver disease.
    Han HS, Kim SG, Kim YS, Jang SH, Kwon Y, Choi D, Huh T, Moon E, Ahn E, Seong JK, Kweon HS, Hwang GS, Lee DH, Cho KW, Koo SH.
    Mol Metab; 2022 Jan 01; 55():101402. PubMed ID: 34838715
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.